JP5026083B2 - 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 - Google Patents

神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 Download PDF

Info

Publication number
JP5026083B2
JP5026083B2 JP2006538375A JP2006538375A JP5026083B2 JP 5026083 B2 JP5026083 B2 JP 5026083B2 JP 2006538375 A JP2006538375 A JP 2006538375A JP 2006538375 A JP2006538375 A JP 2006538375A JP 5026083 B2 JP5026083 B2 JP 5026083B2
Authority
JP
Japan
Prior art keywords
nrp
seq
cells
neuronal
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511210A5 (https=
JP2007511210A (ja
Inventor
フランク シーグ
トルシュテン ゴルバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curonz Holdings Co Ltd
Original Assignee
Curonz Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curonz Holdings Co Ltd filed Critical Curonz Holdings Co Ltd
Publication of JP2007511210A publication Critical patent/JP2007511210A/ja
Publication of JP2007511210A5 publication Critical patent/JP2007511210A5/ja
Application granted granted Critical
Publication of JP5026083B2 publication Critical patent/JP5026083B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
JP2006538375A 2003-10-31 2004-11-01 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 Expired - Fee Related JP5026083B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US51601803P 2003-10-31 2003-10-31
US60/516,018 2003-10-31
US58504104P 2004-07-02 2004-07-02
US60/585,041 2004-07-02
US61627104P 2004-10-05 2004-10-05
US60/616,271 2004-10-05
PCT/US2004/036203 WO2005042561A2 (en) 2003-10-31 2004-11-01 Neural regeneration peptides and methods of use

Publications (3)

Publication Number Publication Date
JP2007511210A JP2007511210A (ja) 2007-05-10
JP2007511210A5 JP2007511210A5 (https=) 2007-08-23
JP5026083B2 true JP5026083B2 (ja) 2012-09-12

Family

ID=34557374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538375A Expired - Fee Related JP5026083B2 (ja) 2003-10-31 2004-11-01 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法

Country Status (3)

Country Link
EP (1) EP1685151A4 (https=)
JP (1) JP5026083B2 (https=)
WO (1) WO2005042561A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4988711B2 (ja) * 2005-05-06 2012-08-01 クロンズ ホールディングズ カンパニー リミテッド 神経再生ペプチド及びそれを含む処方物
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
BRPI0617823A2 (pt) * 2005-10-31 2011-08-09 Laboratoires Serono Sa uso de sdf-1 para o tratamento e/ou prevenção de doenças neurológicas e composição farmacêutica
WO2009051844A1 (en) 2007-10-17 2009-04-23 Neuren Pharmaceuticals Limited Synthetic analogues of neural regeneration peptides
WO2013112002A1 (ko) * 2012-01-27 2013-08-01 의료법인 성광의료재단 뇌 손상 증세의 경감 또는 완화에 대한 바이오마커
US20160015771A1 (en) * 2012-07-27 2016-01-21 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
JP2016514954A (ja) * 2013-03-08 2016-05-26 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 神経再生ペプチドおよびその使用
AU2014332346B2 (en) * 2013-10-11 2019-01-24 Tarix Pharmaceuticals Ltd. Novel peptide compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006662A1 (en) * 1993-09-01 1995-03-09 Start Technology Partnership Neuron regulatory factor for promoting neuron survival
EP1572887A4 (en) * 2001-08-24 2008-12-24 Neuren Pharmaceuticals Ltd NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE

Also Published As

Publication number Publication date
WO2005042561A3 (en) 2006-10-12
EP1685151A4 (en) 2009-04-22
EP1685151A2 (en) 2006-08-02
JP2007511210A (ja) 2007-05-10
WO2005042561A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US7563862B2 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
US20110306557A1 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
Wang et al. Four subtypes of protease‐activated receptors, co‐expressed in rat astrocytes, evoke different physiological signaling
Bénard et al. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
US9028810B2 (en) Composition for inducing migration of neural stem cells containing periostin as effective ingredient
JP5026083B2 (ja) 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
JP5094395B2 (ja) Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置
JP2000501416A (ja) ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
JP4312054B2 (ja) 生物学的活性ペプチドおよびそれを用いた損傷神経の修復
Gorba et al. Neural regeneration protein is a novel chemoattractive and neuronal survival-promoting factor
EP1888635B1 (en) Neural regeneration peptides and methods for their use
JP5019206B2 (ja) 神経突起伸長制御タンパク質
JP2008545388A (ja) 神経再生の制御に有用である核酸及びポリペプチド
JP5581723B2 (ja) 神経突起伸長促進剤
US7662620B2 (en) Human and mammalian stem cell-derived neuron survival factors
KR20010012826A (ko) 신경교 세포주-유래 향신경성 인자 수용체
WO2023077133A2 (en) Controlling homeostatic regulatory circuitry in hypothalamus
KR101437007B1 (ko) 시냅스돌기 밀도를 증가시키는 뉴리틴 단백질
JP2002514386A (ja) ヒトｆｇｆ遺伝子および遺伝子発現産物
KR20130009104A (ko) 항우울증 치료를 위한 뉴리틴 단백질
JP2004517917A (ja) 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法とその使用
Bradoo Discovery of the Novel, MouFSnrp Gene and the Characterisation of Its in Situ Expression Profile During Mouse Neurogenesis
Hunt Molecular approaches to axonal regeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110808

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120529

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120620

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5026083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees